Featured on Jan 9th, 2023

BIO89-100

Treatment for Liver & Metabolic Disorders

CHECK IT OUT
24310E1C-EBF7-4954-88E9-CBE887B9E730.png

A novel long-acting glycopegylated fibroblast growth factor 21 analogue; the BIO89-100 Treatment for Liver & Metabolic Disorders could become a therapy for NASH (nonalcoholic steatohepatitis) given its ability to address the key liver pathologies (steatosis & fibrosis) & underlying metabolic dysregulation in NASH patients.

Hunted by @nigelmarkdias
treatment-for-liver-and-metabolic-disorders
liver-treatment
diabeties-treatment
biotech

$0.00·0 votes·0 comments

No comments yet
LoginSign Up

Most Recent

1
Harmonized
Harmonized
The AI Doc Editor
$0.00· 4· 0
38.07
2
Teamsaver
Teamsaver
Where team updates turn into happiness
$0.00· 7· 0
56.69
3
Wowo
Wowo
Learn Words & Languages
$0.00· 5· 0
31.02
Invalid response id: 1